Continue Reading FDA Seeks Comments on Revised Draft Guidance for Communicating Scientific Information on Unapproved Uses of Approved/Cleared Medical Products
  • Yesterday, Janet Woodcock, M.D., the Principle Deputy Commissioner for the Office of the FDA Commissioner, released a statement regarding the Agency’s approach towards cannabidiol (CBD) and its application in the
Continue Reading FDA Concludes that New Regulatory Frameworks for Foods and Supplements Containing Cannabidiol are Needed, Will Work with Congress
  •  We previously reported on FDA’s November 24, 2021 tentative response denying requests in two citizens petitions (June 1, 2021 Council for Responsible Nutrition (CRN) petition and August 18, 2021 Natural

Continue Reading FDA Confirms N-acetyl-L-cysteine (NAC) is Excluded From the Dietary Supplement Definition and Leaves Open Potential Rulemaking to Allow the use of NAC in Dietary Supplements